FDA PMA FDA Class 3 Approved 🇺🇸 United States

System, Laser, Fiber Optic, Photodynamic Therapy

PMA: P940010 · Supplement: S011 · Decision Mar 21, 2014
Classifications
1
FEI Numbers
1
Registration Numbers
1

Basic Information

Device Name
System, Laser, Fiber Optic, Photodynamic Therapy
Trade Name
OPTIGUIDE FIBER OPTIC DIFFUSER (DCYL CYLINDRICAL DIFFUSER SERIES)
PMA Number
P940010
Supplement Number
S011
Device Class
FDA Class 3
Product Code
MVG
Generic Name
SYSTEM, LASER, FIBER OPTIC, PHOTODYNAMIC THERAPY
Medical Specialty
Unknown
Advisory Committee
General, Plastic Surgery
Decision
Approved
Decision Code
APPR
Decision Date
March 21, 2014
Date Received
September 13, 2013
Supplement Type
Real-Time Process
Supplement Reason
Change Design/Components/Specifications/Material
Expedited Review
N

Advisory Committee Statement

APPROVAL FOR:1) A CHANGE IN THE MATERIAL OF THE TUBING CAP PLACED OVER THE DIFFUSER TIP FROM A POLYCARBONATEMATERIAL TO AN ETFE TUBING MATERIAL;2) THE USE OF HEAT BONDING FOR THE ETFE TUBING MATERIAL IN PLACE OF THE ADHESIVE BONDING PRESENTLY USED FOR THE TUBING CAP;3) ELIMINATION OF THE ORANGE SHEATH PRESENTLY ADDED OVER THE INACTIVE LENGTH OF THE PRESENTLYMARKETED FIBER OPTIC DIFFUSERS; AND4) MODIFICATION OF THE DIFFUSER TIP, SPECIFICALLY:A) USE OF A SILVER MIRROR TO REPLACE THE DIELECTRIC MATERIAL PRESENTLY USED;B) THE USE OF A SILICON DIFFUSER MIX BETWEEN THE END OF THE FIBER CORE AND DIELECTRIC MIRROR;C) AND THE ADDITION OF DIFFUSER SHRINK TUBING TO THE DISTAL END.THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME OPTIGUIDE FIBER OPTIC DIFFUSERDCYL 700 SERIES AND IS INDICATED FOR USE IN PHOTODYNAMIC THERAPY WITH PHOTOFRIN(PORFIMER SODIUM) FOR INJECTION FOR: 1) PALLIATION OF PATIENTS WITH COMPLETELY OBSTRUCTING ESOPHAGEAL CANCER OR PATIENTS WITH PARTIALLYOBSTRUCTING ESOPHAGEAL CANCER WHO, IN THE OPINION OF THEIR PHYSICIAN, CANNOT BE SATISFACTORILYTREATED WITH ND:YAG LASER THERAPY;2) REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLYOBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER (NSCLC);3) TREATMENT OF MICROINVASIVE ENDOBRONCHIAL NSCLC IN PATIENTS FOR WHOM SURGERY AND RADIOTHERAPY ARE NOT INDICATED; AND4) ABLATION OF HIGH-GRADE DYSPLASIA (HGD) IN BARRETTS ESOPHAGUS (BE) AMONG PATIENTS WHO ARE NOT CANDIDATES FOR ESOPHAGECTOMY.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
MVG System, Laser, Fiber Optic, Photodynamic Therapy